Gilbert & Cook Inc. Purchases 700 Shares of Pfizer Inc. (NYSE:PFE)

Gilbert & Cook Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 25,243 shares of the biopharmaceutical company’s stock after purchasing an additional 700 shares during the period. Gilbert & Cook Inc.’s holdings in Pfizer were worth $731,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Swiss National Bank grew its holdings in Pfizer by 0.6% during the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock valued at $486,762,000 after purchasing an additional 100,900 shares during the period. Thrivent Financial for Lutherans grew its holdings in Pfizer by 14.5% during the third quarter. Thrivent Financial for Lutherans now owns 846,582 shares of the biopharmaceutical company’s stock valued at $24,500,000 after purchasing an additional 107,346 shares during the period. Claro Advisors LLC grew its holdings in Pfizer by 2.2% during the third quarter. Claro Advisors LLC now owns 41,762 shares of the biopharmaceutical company’s stock valued at $1,209,000 after purchasing an additional 879 shares during the period. Ceera Investments LLC grew its holdings in Pfizer by 13.2% during the third quarter. Ceera Investments LLC now owns 52,051 shares of the biopharmaceutical company’s stock valued at $1,506,000 after purchasing an additional 6,065 shares during the period. Finally, Chesapeake Capital Corp IL bought a new stake in Pfizer during the third quarter valued at about $293,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Wolfe Research initiated coverage on Pfizer in a research report on Friday. They issued an “underperform” rating and a $25.00 price objective on the stock. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Down 4.7 %

Shares of PFE stock opened at $24.80 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock’s 50 day simple moving average is $28.64 and its two-hundred day simple moving average is $28.66. The company has a market cap of $140.54 billion, a PE ratio of 33.51, a price-to-earnings-growth ratio of 0.79 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the prior year, the business posted ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.77%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.